Liver Health Supplements - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The liver health supplements market size is expected to increase from USD 14.65 billion in 2025 to USD 15.23 billion in 2026 and reach USD 19 billion by 2031, growing at a CAGR of 4.52% over 2026-2031. This report is Segmented by Product (Vitamins & Minerals, and More), Dosage Form (Capsules, and More), End User (Adults 19-64 Years, and More), Distribution Channel (Online Retailers, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Liver Health Supplements Market Trends and Insights

Escalating Incidence of NAFLD and Metabolic Syndrome

MASLD now affects approximately 30% of the adult population worldwide, with a prevalence of 25.6% among adults and around 10% among children. About 20% of MASLD cases progress to metabolic-associated steatohepatitis, elevating risks of cirrhosis and hepatocellular carcinoma. Primary-care physicians increasingly recommend adjunctive nutraceuticals despite 2024 EASL-EASD-EASO guidance that found insufficient therapeutic evidence. Pediatric MASLD growth is driving the development of child-friendly formats, while adults view supplements as low-risk preventive aids, even as institutional adoption remains limited.

Rising Consumer Shift Toward Herbal & Plant-Based Nutraceuticals

Turmeric-based liver products are projected to post 28% year-over-year Amazon sales growth through 2024. Cultural familiarity with Ayurveda and Traditional Chinese Medicine reinforces demand for milk thistle, dandelion root, and bupleurum. However, a 2024 review identified that 7% of U.S. adults ingest botanicals linked to hepatotoxicity, and herb-induced liver injury shows 5-19% mortality. FDA’s tightened 2024 NDI rules raise the bar on safety data, rewarding brands that obtain USP or NSF certifications.

Fragmented & Stringent Global Supplement Regulations

FDA’s 2024 NDI guidance demands safety submissions for post-1994 ingredients, inflating compliance budgets by USD 50,000-150,000 per SKU. EFSA bars liver-health claims without randomized trials, India’s FSSAI and China’s NMPA require country-specific dossiers, and timelines stretch 18-36 months. Smaller brands lacking regulatory staff often face delayed launches and higher costs, which pushes them toward e-commerce gray zones, while multinationals deploy global compliance teams.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of E-Commerce & Direct-To-Consumer Distribution
• Adoption of Precision Micro-Encapsulation for Higher Bioavailability
• Adulteration & Contaminant-Related Safety Concerns

Segment Analysis

Herbal supplements captured 45.32% of 2025 revenue, underscoring consumer preference for plant-based options. Turmeric, milk thistle, and dandelion root dominate shelves, while turmeric SKUs logged a 28% Amazon sales jump through 2024. The “Other Products” category, including NAC and liposomal glutathione, is projected to achieve a 6.43% CAGR, reflecting renewed FDA clarity that has allowed NAC to remain within the supplement category. Brands licensing Siliphos or liposomal technologies differentiate on efficacy rather than price, positioning the category for outsized gains.

Siliphos reduces the required silymarin dose from 420 mg to approximately 100 mg while maintaining the endpoints. Jarrow Formulas and Life Extension have already reformulated their flagship lines, whereas commodity suppliers struggle with shrinking margins. Because neither the FDA nor EFSA mandates bioavailability proof, early-mover brands are banking on premium pricing before standards tighten, steering the liver health supplements market toward two-tier competition.

Capsules accounted for 46.76% of 2025 sales, driven by precise dosing and consumer familiarity. Enteric coatings are now featured in many premium SKUs, mitigating gastric discomfort and enhancing reviews. Tablets trail due to binders and slower disintegration. Powders, aided by smoothie-friendly positioning and 15-20% lower manufacturing costs, are poised for 6.87% CAGR. Search volume for “liver detox powder” rose 42% in 2024, signaling sustained demand.

NOW Foods’ 2024 Liver Refresh powder blends milk thistle, NAC, and methionine, targeting fitness users. Gummies and liquid drops cater to pediatric and geriatric users, yet formulators wrestle with sugar and stability constraints. The FDA’s December 2024 “healthy” label update favors powders and liquids that can display claims prominently, reinforcing the channel’s momentum.

Complete Report Scope:

• By Product
  • Vitamins & Minerals
  • Herbal Supplements
  • Other Products
• By Dosage Form
  • Capsules
  • Tablets
  • Powder
  • Others
• By End User
  • Adults (19-64 Years)
  • Geriatric (65+ Years)
  • Pediatric (0-18 Years)
• By Distribution Channel
  • Online Retailers
  • Pharmacies & Drugstores
  • Supermarkets / Hypermarkets
  • Specialty Stores
  • Practitioner / Clinic Dispensed
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest Of Asia-Pacific
  • Middle East And Africa
    • GCC
    • South Africa
    • Rest Of Middle East And Africa
  • South America
    • Brazil
    • Argentina
    • Rest Of South America

Geography Analysis

North America generated 42.67% of global revenue in 2025, driven by high per-capita spending, mature retail networks, and the FDA’s 2024 guidance that clarified compliance expectations. Corporate wellness screenings mainstreamed liver enzyme testing, prompting asymptomatic adults to consider preventive supplementation. Market growth, however, is slowing as penetration surpasses 60% across key demographics and as regulatory costs rise.

Asia-Pacific is projected to have a 5.64% CAGR to 2031, propelled by rising disposable income, herbal heritage, and liberalizing rules. The April 2024 Nestlé-Dr. Reddy’s joint venture brought Nature’s Bounty to India’s INR 47,000-crore nutraceutical arena. India’s FSSAI now approves Ayurvedic formulations in 12-18 months, while China broadens its “blue hat” registration to imported botanicals. Localization - turmeric-ashwagandha blends in India, bupleurum-schisandra mixes in China - helps multinationals resonate with regional traditions.

Europe, the Middle East & Africa, as well as South America, contribute smaller shares yet present focused opportunities. Gulf Cooperation Council nations buy premium Western SKUs via medical tourism corridors, while South America’s wellness influencers drive awareness among urban millennials. EFSA’s stringent claim rules dampen European growth, but high consumer trust enables premium pricing once claims are validated, sustaining the liver health supplements market in the region.

List of Companies Covered in this Report:

• Amway
• Blackmores
• BodyBio
• Cymbiotika
• Enzymedica
• Gaia Herbs
• GNC
• Himalaya
• Integria Healthcare (Thompson’s)
• Irwin Naturals
• Jarrow Formulas
• Life Extension
• Nature's Bounty
• Nature's Way Brands
• NOW Foods
• Nutralife Health Products
• Pure Encapsulations
• Renew Life Formulas
• Solgar
• Swanson Health Products
• Swisse Wellness

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support